HK Surge Stock Analysis: 朸浚国际 (01355.HK)

On December 22, 2025, 朸浚国际 (01355.HK) appeared on the East Money App’s HK market surge list [1]. The key catalysts are the company’s strategic transformation and upcoming rebranding. On December 23, 2025, it will change its name to “Biosysen Limited” (生物系统工程有限公司), signaling a shift from traditional hotel operations/consulting to healthcare, beauty, and bio-system engineering [0]. This pivot was foreshadowed by a September 2025 share placement to fund new business development [0]. A prior 15.81% price increase [0] aligns with its current surge list appearance.

1. The name change is a strong rebranding effort, helping investors perceive the company as a high-growth sector (healthcare/bio-engineering) player instead of its mature hotel business [0].
2. The September 2025 share placement demonstrates commitment to the new direction, providing capital for expansion [0].
3. The surge reflects positive market sentiment toward the transformation, as investors anticipate higher growth potential in the new sectors [1].

• Entry into high-growth healthcare, beauty, and bio-system engineering sectors with strong global and Asia-Pacific growth potential [0].
• Strategic rebranding can attract new investors interested in growth industries [0].

• Execution risk in transitioning to entirely new business sectors requiring different expertise and capabilities [0].
• Uncertainty about profitability and timeline for returns from the new business segments [0].
• The September 2025 share placement may have diluted existing shareholders [0].

朸浚国际 (01355.HK) appeared on the East Money App’s HK market surge list on December 22, 2025, driven by an upcoming name change to “Biosysen Limited” and a strategic pivot from hotel operations to healthcare, beauty, and bio-system engineering. The company raised funds for this transformation via a September 2025 share placement, and the market previously reacted with a 15.81% price increase. While the shift presents opportunities in high-growth sectors, it also carries execution and profitability risks.